FDA WARNING_LETTER - Metuchen Pharmaceuticals, LLC. - September 03, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA's Office of Prescription Drug Promotion (OPDP) issued a Warning Letter to Metuchen Pharmaceuticals, LLC, regarding promotional materials for STENDRA® (avanafil) tablets. The review of a direct-to-consumer print ad (STEN-MET-28) and display banners (STEN-MET-02 and STEN-MET-06) revealed false or misleading claims about Stendra's risks and efficacy, misbranding the drug under the FD&C Act (21 U.S.C. 352(a) & (n); 321(n), 331(a); 21 CFR 202.1(e)(3)(ii), (iii); (e)(5); (e)(7)(viii)).
Specifically, the print ad suggested a new, unapproved use: "Treat ED and Reduce Risk of Heart Failure with a PDE-5 Inhibitor," for which Stendra lacks approval and adequate directions for use, further misbranding it (21 U.S.C. 352(f)(1); 331(a); 21 CFR 201.5; 201.100; 201.115; 201.128). This is concerning given Stendra's cardiovascular risks and contraindication in patients with New York Heart Association Class 2 or
ID · 20fc6459-2221-47fd-8828-b662124b3517
Full citation text and observation details available on the Dashboard.